ScientiaLux
Index
QF-Pro Home › QF-Pro Glossary › CXCL10
Chemokine

CXCL10

The most-studied CXCR3 ligand—combining T cell chemoattraction with angiostatic activity and serving as a measurable serum biomarker.

View
Definition
CXCL10 (Interferon gamma-Induced Protein 10, IP-10) is an IFN-γ-inducible CXC chemokine with dual anti-tumor mechanisms: it recruits CXCR3+ effector T cells to the tumor immune microenvironmentLoading... and directly inhibits tumor angiogenesis. Of the three CXCR3 ligands, CXCL10 has the broadest clinical evidence base and unique utility as a serum-measurable biomarker for non-invasive monitoring of anti-tumor immune activity.
Dual Mechanism
T cell recruitment plus angiostasis
Broadest Evidence
Most clinically validated CXCR3 ligand
Serum Measurable
Non-invasive monitoring via blood levels
ICI Response Predictor
Baseline and on-treatment levels predict outcomes

Dual Anti-Tumor Mechanisms

CXCL10 exerts anti-tumor effects through two complementary pathways:

  • Immune recruitment: Like CXCL9Loading..., CXCL10 binds CXCR3 on CD8+ T cells and NK cells, establishing chemokine gradients that guide effector cells into the TiMELoading...
  • Angiostasis: CXCL10 directly inhibits endothelial cell proliferation and migration, suppressing the formation of new blood vessels that tumors require for growth beyond ~2mm

This dual mechanism means CXCL10 attacks tumors from two directions simultaneously: recruiting immune killers while cutting off the tumor's blood supply.

Simplified

Two Ways to Fight Tumors:

1. Recruit T cells: Attracts immune cells that can kill tumor cells

2. Starve the tumor: Blocks blood vessel growth that tumors need to survive

This dual action makes CXCL10 unique among the CXCR3 chemokines.

Serum Biomarker Utility

Unlike most tumor biomarkers that require tissue biopsy, CXCL10 is reliably detectable in peripheral blood. Serum CXCL10 levels reflect systemic IFN-γ-driven immune activation and can be measured using standard ELISA or Luminex immunoassays.

Clinical applications include:

  • Baseline stratification: Pre-treatment serum CXCL10 levels identify patients with active anti-tumor immunity
  • Dynamic monitoring: Serial measurements track immune response activation during immunotherapyLoading...
  • Response prediction: Early rises in CXCL10 on-treatment correlate with clinical benefit
Simplified

Blood Test, Not Biopsy: CXCL10 can be measured in a simple blood draw—no tumor biopsy needed. This allows doctors to:

• Check immune activity before starting treatment

• Track changes during treatment

• Detect early signs of response or resistance

Pan-Cancer Evidence

CXCL10's role as an immunotherapy biomarker spans multiple tumor types:

However, in HR+ breast cancerLoading..., Napolitano et al. (2026) found that high CXCL10 expression was associated with shorter relapse-free survival (HR 1.79) in endocrine-treated patients. CD8+ T cell coculture conditioned media—rich in CXCR3 ligands—promoted estrogen-independent tumor cell growth, suggesting the chemokines may directly fuel endocrine resistance.

Simplified

Works Across Cancer Types: CXCL10 predicts immunotherapy response in melanoma, lung cancer, kidney cancer, and more.

The Exception: In HR+ breast cancer, high CXCL10 predicted worse outcomes on hormone therapy (HR 1.79; Napolitano et al., 2026). The chemokine that recruits anti-tumor T cells may also help tumor cells grow without estrogen.

Simple Recruitment Signal
Chemokines are passive directional cues—their presence merely attracts immune cells to a location without affecting tumor cells directly.
Multifunctional Mediator
CXCL10 has direct anti-tumor effects (angiostasis) and context-dependent roles—measurable non-invasively in serum as a dynamic biomarker of immune activation.

Clinical Significance

  • Dual anti-tumor action: Recruits CD8+ T cells to TiMELoading... while inhibiting tumor angiogenesis
  • Serum biomarker: Non-invasive measurement enables longitudinal monitoring of immune activation
  • HR+ breast cancer: High expression associated with shorter RFS (HR 1.79) in endocrine-treated patients (Napolitano et al., J Clin Invest. 2026;136(3):e188458)
  • Pan-cancer predictor: Validated as ICILoading... response biomarker across melanoma, NSCLCLoading..., and ccRCCLoading...

Connected Terms

Share This Term
Term Connections